Quantcast

News from First Joint US Conference on Arthritis Syndromes That Cause Back Pain

July 31, 2014

NORWALK, Conn., July 31, 2014 /PRNewswire/ — UBM Medica US announces that Rheumatology Network, a leading online community for Rheumatologists, offers special coverage of the first joint meeting of two societies dedicated to related forms of arthritis, collectively known as spondyloarthritis.

Spondyloarthritis is an important and treatable cause of chronic back pain. Psoriatic arthritis, which causes inflammation of the joints often including the lower back, arises in about 10% of patients with the skin condition psoriasis, affecting more than 500,000 people in the United States

Invited to cover the combined meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) and SPARTAN (Spondyloarthritis Research and Treatment Network) in New York earlier this month, Rheumatology Network presents special reports on:

    --  A study now underway to create a blood test that will predict the risk
        of painful psoriatic arthritis among patients who have psoriasis.
    --  Efforts to make psoriatic arthritis harder to miss. While many primary
        care doctors and dermatologists are familiar with the skin condition
        known as psoriasis, they are not sufficiently alert to the fact that
        joint pain in the same patients may be related to the skin symptoms and
        may require specific treatment.
    --  A strong role that patients are taking in the process of crafting
        guidelines for psoriatic arthritis. Patients at the conference discussed
        ways in which their perception of the disease differs from that of
        doctors, which may affect treatment.
    --  New guidelines for the treatment of spondyloarthritis that are
        customized for patients in North America.

About UBM Medica US

Addressing today’s healthcare information needs, UBM Medica US, delivers strategic, integrated communications solutions and comprehensive reach — online, in print, via custom programs and live events. Improving the effectiveness of healthcare through information and education, UBM Medica US provides unbiased clinical, practical, and business information for physicians, providers and payers resulting in improved quality of care for patients around the world. Through journals, magazines, online communities, live and digital events, and other valuable resources, UBM Medica US also delivers comprehensive communication solutions for the pharmaceutical and related industries. Online communities include CancerNetwork.com, ConsultantLive.com, DiagnosticImaging.com, RheumatologyNetwork.com, OBGYN.net, PhysiciansPractice.com, PsychiatricTimes.com and SearchMedica.com. UBM Medica US is part of UBM Connect which, through a range of aligned interactive environments, both physical and digital – increases business effectiveness for both customers and audiences through meaningful experiences, knowledge and connections. Headquartered in New York, UBM Connect brings together UBM’s healthcare business, UBM Medica US; UBM Canon’s advanced design and manufacturing event, online and print brands; UBM Connect New York’s catering, cruise shipping, customer management, and fine, specialty and custom chemical communities; and UBM Mexico’s concrete show. For more information, visit www.UBMMedicaUS.com.

About UBM plc

UBM plc is a global events-led marketing services and communications company. We help businesses do business, bringing the world’s buyers and sellers together at events and online, as well as producing and distributing news and specialist content. Our 5,500 staff in more than 30 countries are organized into expert teams which serve commercial and professional communities, helping them to do business and their markets to work effectively and efficiently.

For more information, go to www.ubm.com; follow us on Twitter at @UBM_plc to get the latest UBM corporate news.

Media contact:

Jason J. Golden

Content Marketing Manager

203-523-7040

jason.golden@ubm.com

SOURCE UBM Medica US


Source: PR Newswire



comments powered by Disqus